Investment Value Of Listed Companies In Chinese Pharmaceutical Industry Research

Biological medicine industry is classified as one of the biggest categories of industry,and has "never fading sunrise industry" reputation in the investment field.Biological medicine industry is a special industry closely related to the national economy and people’s livelihood.China has formed a relatively complete medical industry system and medical circulation network,and developed into the world pharmaceutical power.The status of the pharmaceutical industry in the national economy has steadily improved,and the proportion of the main economic indicators in the total industrial output has shown a steady growth trend.It is one of the stable sources of industrial efficiency in China.Therefore,it is of great practical significance to study the investment value of pharmaceutical industry.This paper uses PEST analysis method to analyze the development status and problems of China’s pharmaceutical industry.Based on the relative valuation method,the paper selected data from 20012-2016 to study the investment value of listed companies in pharmaceutical industry.In this paper,Hengrui Medical,Kangmei Pharmaceutical,Yunnanbaiyao,Fosun Pharma and Dong’e E-Jiao were selected as the research object.Based on their financial data of the last five years,the paper analyzed the profit of the sample stock from the profit ability,growth ability,debt paying ability,operation ability.Through comprehensive analysis,the pharmaceutical industry has both consumption and high-tech characteristics of the industry,there is great room for development and great development momentum,but also maintain rapid and stable growth,and will be concerned about investors.The future for a long time,the pharmaceutical sector is still able to significantly outperform the market.The article believes that China’s pharmaceutical industry has great investment value and investment opportunities,it is recommended that investors concerned.